Effectiveness of the Ad26.COV2.S (Johnson & Johnson) Coronavirus Disease 2019 (COVID-19) Vaccine for Preventing COVID-19 Hospitalizations and Progression to High Disease Severity in the United States

Article Surgery

SARS-CoV-2-specific humoral and cell-mediated immune responses after immunization with inactivated COVID-19 vaccine in kidney transplant recipients (CVIM 1 study)

Jackrapong Bruminhent et al.

Summary: Solid organ transplant recipients who received inactivated SARS-CoV-2 vaccination showed weak humoral immunity but comparable cell-mediated immunity responses compared to immunocompetent individuals.

AMERICAN JOURNAL OF TRANSPLANTATION (2022)

Add to Collection

Article Medicine, General & Internal

Association Between 3 Doses of mRNA COVID-19 Vaccine and Symptomatic Infection Caused by the SARS-CoV-2 Omicron and Delta Variants

Emma K. Accorsi et al.

Summary: Assessing the performance of COVID-19 vaccines against the Omicron variant is crucial for public health guidance. This study found that receiving three doses of mRNA COVID-19 vaccine was associated with a lower likelihood of symptomatic SARS-CoV-2 infection compared to being unvaccinated or receiving two doses. These findings suggest that three doses of mRNA vaccine provide protection against both Omicron and Delta variants, though the protection against Omicron may be slightly lower.

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2022)

Add to Collection

Article Immunology

Effectiveness of mRNA Vaccines Against COVID-19 Hospitalization by Age and Chronic Medical Conditions Burden Among Immunocompetent US Adults, March-August 2021

Nathaniel M. Lewis et al.

Summary: The effectiveness of COVID-19 vaccines in reducing hospitalizations is high among immunocompetent adults, especially those without chronic medical conditions. However, the effectiveness decreases with increasing comorbidity burden.

JOURNAL OF INFECTIOUS DISEASES (2022)

Add to Collection

Article Medicine, General & Internal

Final Analysis of Efficacy and Safety of Single-Dose Ad26.COV2.S

J. Sadoff et al.

Summary: The Ad26.COV2.S vaccine was found to be 52.9% effective against moderate to severe-critical Covid-19 after a single dose, with protection lasting for at least 6 months. Efficacy varied depending on the Covid-19 variant, but higher protection was observed against severe cases, medical intervention, and death compared to other outcomes.

NEW ENGLAND JOURNAL OF MEDICINE (2022)

Add to Collection

Article Multidisciplinary Sciences

SARS-CoV-2 vaccine protection and deaths among US veterans during 2021

Barbara A. Cohn et al.

Summary: This study reports the effectiveness of vaccines against SARS-CoV-2 infection and death in veterans, with a decline in vaccine effectiveness observed for all vaccine types. The decline was greatest for the Janssen vaccine. However, vaccination remained protective against death for individuals who became infected during the Delta variant surge. The study also found variations in the vaccine effectiveness against death among different age groups.

SCIENCE (2022)

Add to Collection

Article Public, Environmental & Occupational Health

Use of the Janssen (Johnson & Johnson) COVID-19 Vaccine: Updated Interim Recommendations from the Advisory Committee on Immunization Practices — United States, December 2021

Sara E. Oliver et al.

MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT (2022)

Add to Collection

Article Immunology

Effectiveness of Severe Acute Respiratory Syndrome Coronavirus 2 Messenger RNA Vaccines for Preventing Coronavirus Disease 2019 Hospitalizations in the United States

Mark W. Tenforde et al.

Summary: From March to May 2021, full vaccination using authorized mRNA products was associated with 87.1% protection against COVID-19 hospitalization among US adults, with lower effectiveness in adults with immunosuppression compared to those without. Vaccination was beneficial for patients with immunosuppression, but the effectiveness was lower in this population.

CLINICAL INFECTIOUS DISEASES (2022)

Add to Collection

Review Immunology

Vaccines based on replication incompetent Ad26 viral vectors: Standardized template with key considerations for a risk/benefit assessment

Jerome Custers et al.

Summary: This article reviews the safety and efficacy of Ad26 vector-based vaccines in clinical trials, showing good tolerability and immunogenicity in multiple studies. New developments in Ad26-based vaccines, including a COVID-19 vaccine currently in phase 3 clinical evaluation, are promising for vaccine development.

VACCINE (2021)

Add to Collection

Article Medicine, General & Internal

Interim Results of a Phase 1-2a Trial of Ad26.COV2.S Covid-19 Vaccine

J. Sadoff et al.

Summary: The study conducted a multicenter, placebo-controlled, phase 1-2a trial, with participants randomly assigned to receive the Ad26.COV2.S vaccine. The results showed that the safety and immunogenicity profiles of the vaccine support further development.

NEW ENGLAND JOURNAL OF MEDICINE (2021)

Add to Collection

Article Medicine, General & Internal

Association Between mRNA Vaccination and COVID-19 Hospitalization and Disease Severity

Mark W. Tenforde et al.

Summary: This study evaluated the association between mRNA COVID-19 vaccines and COVID-19 hospitalization, as well as disease progression to critical illness among hospitalized patients. The results showed that vaccination with mRNA COVID-19 vaccines significantly decreased the likelihood of COVID-19 hospitalization and disease progression to death or mechanical ventilation.

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2021)

Add to Collection

Article Medicine, General & Internal

The Johnson & Johnson Vaccine for COVID-19

Edward H. Livingston et al.

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2021)

Add to Collection

Editorial Material Medicine, General & Internal

Approaches for Optimal Use of Different COVID-19 Vaccines Issues of Viral Variants and Vaccine Efficacy

John P. Moore

Summary: Given the emergence of coronavirus variants and the authorization of the Johnson & Johnson vaccine, strategies to maximize vaccine efficacy and distribution include reserving the vaccine for young healthy populations, boosting with a single-dose mRNA vaccine, and single mRNA immunization for those with prior SARS-CoV-2 infection.

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2021)

Add to Collection

Article Public, Environmental & Occupational Health

The Advisory Committee on Immunization Practices’ Interim Recommendation for Use of Janssen COVID-19 Vaccine — United States, February 2021

Sara E. Oliver et al.

MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT (2021)

Add to Collection

Article Public, Environmental & Occupational Health

The Advisory Committee on Immunization Practices’ Interim Recommendations for Additional Primary and Booster Doses of COVID-19 Vaccines — United States, 2021

Sarah Mbaeyi et al.

MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT (2021)

Add to Collection

Article Public, Environmental & Occupational Health

Safety Monitoring of the Janssen (Johnson & Johnson) COVID-19 Vaccine — United States, March–April 2021

David K. Shay et al.

MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT (2021)

Add to Collection

Article Public, Environmental & Occupational Health

Updated Recommendations from the Advisory Committee on Immunization Practices for Use of the Janssen (Johnson & Johnson) COVID-19 Vaccine After Reports of Thrombosis with Thrombocytopenia Syndrome Among Vaccine Recipients — United States, April 2021

Jessica R. MacNeil et al.

MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT (2021)

Add to Collection

Article Critical Care Medicine

BNT162b2 COVID-19 vaccine and correlates of humoral immune responses and dynamics: a prospective, single-centre, longitudinal cohort study in health-care workers

Yaniv Lustig et al.

Summary: The study assessed early antibody responses after Pfizer-BioNTech BNT162b2 COVID-19 vaccine in Israeli healthcare workers. Results showed that 77% of participants had positive IgG response at week 3 after the first vaccine dose, with lower responses in older and immunosuppressed individuals. Timely second dose vaccinations are particularly important for these populations to enhance antibody responses and reduce breakthrough infections.

LANCET RESPIRATORY MEDICINE (2021)

Add to Collection

Article Public, Environmental & Occupational Health

Sustained Effectiveness of Pfizer-BioNTech and Moderna Vaccines Against COVID-19 Associated Hospitalizations Among Adults — United States, March–July 2021

Mark W. Tenforde et al.

MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT (2021)

Add to Collection

Article Public, Environmental & Occupational Health

Comparative Effectiveness of Moderna, Pfizer-BioNTech, and Janssen (Johnson & Johnson) Vaccines in Preventing COVID-19 Hospitalizations Among Adults Without Immunocompromising Conditions — United States, March–August 2021

Wesley H. Self et al.

MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT (2021)

Add to Collection

Effectiveness of the Ad26.COV2.S (Johnson & Johnson) Coronavirus Disease 2019 (COVID-19) Vaccine for Preventing COVID-19 Hospitalizations and Progression to High Disease Severity in the United States

Related references

Export Citation

Share Paper